

Letters

RESEARCH LETTER

Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

Symptom monitoring during chemotherapy via web-based patient-reported outcomes (PROs) was previously demonstrated to lengthen survival in a single-center study.¹ A multicenter randomized clinical trial compared web-based monitoring vs standard scheduled imaging to detect symptomatic recurrence in patients with lung cancer following initial treatment. A planned interim analysis (9-month follow-up) found a significant survival benefit (19-month survival in the PRO group vs 12 months in the control group).² We now present the final overall survival analysis.




Supplemental content

Methods | As described previously,² in this randomized trial, patients with advanced nonprogressive stage IIA (TXN1) to IV lung cancer were randomly assigned within 3 months of previous treatment to receive either web-based symptom monitoring via the Sentinel PRO system (Hyperion) or standard follow-up with scheduled imaging every 3 to 6 months (the trial protocol is available in Supplement 1). Eligible patients were recruited at 5 centers in France from June 2014 to January 2016. Nonprogressive patients treated for metastatic disease by tyrosine kinase inhibitors, maintenance antiangiogenic or chemotherapy, or immunotherapy were eligible. Allocation was generated centrally and concealed from investigators and participants. The study was reviewed and approved by the ethics review board from the University Hospital at Angers (France). All participants provided written informed consent.

In the PRO group, patients were invited to complete weekly self-reports of 13 common symptoms online between visits. The PRO system automatically triggered an alert email to the treating oncologist when patient-reported symptoms matched predefined criteria for severity and worsening. In both groups, additional imaging could be performed at the treating oncologist's discretion.

The primary outcome was overall survival after 2 years of follow-up, which was selected based on prior pilot research.³ Survival data were gathered from patient follow-up by blinded investigators. After a preplanned interim analysis in January 2016 in which a significant survival improvement was observed, the data and safety monitoring committee mandated cessation of recruitment and crossover of control patients to the intervention. Sixty percent of the prespecified sample size was enrolled when recruitment was halted. The final date of follow-up was December 29, 2017.

Figure 1. Assignment, Follow-up, and Analysis of the Study Patients



At 9 months when recruitment was halted, 10 patients in the intervention group and 27 patients in the control group had died. Of the 34 living patients in the control group, 10 had not relapsed and crossed over to the intervention.

Overall survival was estimated via the Kaplan-Meier method and compared between groups with a log-rank test (SAS version 9.3; SAS Institute). A 2-sided $P < .05$ was considered significant. Analyses were performed on an intention-to-treat basis and with censoring at crossover.⁴


Results | One hundred thirty-three patients were enrolled of whom 12 were ineligible, leaving a study population of 121 (60 in the intervention and 61 in the control group) (Figure 1). Baseline demographic and disease characteristics were well balanced between groups.² The median age was 65 years (range, 36-88 years), 67% were men, 32% had stage III cancer, 63% had stage IV cancer, and 17% had small cell cancer. Following interim analysis, 10 of 34 living patients in the control group had not relapsed and therefore were eligible to cross over to the intervention. No participants were lost to follow-up.

With 2 years of follow-up, 69 deaths were observed: 29 (47.5%) in the intervention group and 40 (66.7%) in the control group. The median overall survival was 22.5 months in the intervention group vs 14.9 months in the control group, without censoring for crossover (hazard ratio, 0.59 [95% CI, 0.37-0.96]; $P = .03$) (Figure 2A). Censoring crossover resulted in a median overall survival of 22.5 months in the intervention group vs 13.5 months in the control group (hazard ratio, 0.50 [95% CI, 0.31-0.81]; $P = .005$) (Figure 2B).

Discussion | Symptom monitoring via weekly web-based PROs following treatment for lung cancer was associated with increased survival compared with standard imaging surveillance. A potential mechanism of action is that symptoms suggesting adverse events or recurrence were detected earlier.

Limitations of this study include conduct only in France, early stopping of the trial and crossover of control patients, and inclusion of patients receiving maintenance therapy, who may have had increased interactions with care teams.

Figure 2. Kaplan-Meier Curves for the Overall Survival (OS) Analysis



A total of 121 patients were included in the intention-to-treat survival analysis. Ten of 34 living patients in the control group were eligible to cross over following the interim analysis. HR indicates hazard ratio.

Fabrice Denis, MD, PhD
 Ethan Basch, MD
 Anne-Lise Septans, PhD
 Jaafar Bennouna, MD, PhD
 Thierry Urban, MD, PhD
 Amylou C. Dueck, PhD
 Christophe Letellier, PhD

Author Affiliations: Institut Inter-régional de Cancérologie Jean Bernard, Le Mans, France (Denis); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (Basch); Weprom, Angers, France (Septans); Thoracic and Digestive Oncology, CHU Nantes, Nantes, France (Bennouna); Service de pneumologie, Centre Hospitalier Universitaire, Angers, France (Urban); Mayo Clinic, Scottsdale, Arizona (Dueck); Normandie Université-CORIA, Rouen, France (Letellier).

Accepted for Publication: October 24, 2018.

Corresponding Author: Fabrice Denis, MD, PhD, Institut Inter-régional de Cancérologie Jean Bernard, 9 rue Beauverger, Le Mans, France (f.denis@cjb72.org).

Author Contributions: Dr Denis had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Denis, Basch, Urban.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Denis, Septans.

Critical revision of the manuscript for important intellectual content: Denis, Basch, Bennouna, Urban, Dueck, Letellier.

Statistical analysis: Denis, Septans, Dueck.

Administrative, technical, or material support: Letellier.

Conflict of Interest Disclosures: Dr Denis reported receiving personal fees from AstraZeneca, Ipsen, SIVAN Innovation, Pfizer, Chugai, and Roche. Dr Basch reported receiving research funding from the National Cancer Institute and Patient-Centered Outcomes Research Institute and personal fees (ie, payment for serving on the scientific advisory board) from the Centers for Medicare & Medicaid Services, SIVAN Innovation, and Noona. Dr Bennouna reported receiving personal fees from Lilly and Merck Sharp & Dohme. Dr Urban reported receiving personal fees from AstraZeneca and Novartis. No other disclosures were reported.

Funding/Support: This study was supported by SIVAN Innovation.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the trial; the collection, management, analysis, and interpretation of the data; the preparation, review, and approval of the manuscript; and the decision to submit for publication. It had the possibility to prevent the submission of the manuscript.

Trial Registration: ClinicalTrials.gov Identifier: [NCT02361099](https://clinicaltrials.gov/ct2/show/study/NCT02361099)

Meeting Presentation: This study was presented at the annual American Society of Clinical Oncology meeting; June 1, 2018; Chicago, Illinois.

Data Sharing Statement: See [Supplement 2](#).

Additional Contributions: We are grateful to the patients who participated in this study and their caregivers. We also thank Claire Lethrosne, MD (Centre Hospitalier Chartres, France), Nicolas Pourel, MD (Institut Sainte Catherine, Avignon, France), Olivier Molinier, MD (Centre Hospitalier, Le Mans, France), Yoann Pointreau, MD, PhD (Institut Inter-régional de Cancérologie Jean Bernard, Le Mans, France), Julien Domont, MD (Institut Inter-régional de Cancérologie Jean Bernard, Le Mans, France), Hugues Bourgeois, MD (Institut Inter-régional de Cancérologie Jean Bernard, Le Mans, France), Héléne Senellart, MD (Institut de Cancérologie de l'Ouest, Nantes, France), Magali Balavoine, MSc (Weprom, Angers, France), and Philippe Solal-Céligny, MD, PhD (Institut de Cancérologie de l'Ouest, Nantes, France), for their collaboration in the conduct and analysis of this trial. None of them received any compensation for their contributions. We also thank French Societies of Radiation Oncology, the National Syndicate of Radiation Oncology, and the French College of Physicians for their support.

- Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA*. 2017;318(2):197-198. doi:[10.1001/jama.2017.7156](https://doi.org/10.1001/jama.2017.7156)
- Denis F, Lethrosne C, Pourel N, et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. *J Natl Cancer Inst*. 2017;109(9). doi:[10.1093/jnci/djx029](https://doi.org/10.1093/jnci/djx029)
- Denis F, Yossi S, Septans AL, et al. Improving survival in patient treated for a lung cancer using self-evaluated symptoms reported through a web application. *Am J Clin Oncol*. 2017;40(5):464-469. doi:[10.1097/JCO.000000000000189](https://doi.org/10.1097/JCO.000000000000189)
- Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. *Commun Stat Theory Methods*. 1991;20:2609-2631. doi:[10.1080/03610929108830654](https://doi.org/10.1080/03610929108830654)